153 related articles for article (PubMed ID: 31109107)
1. Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.
Martin-Martin A; Rivera-Dictter A; Muñoz-Uribe M; López-Contreras F; Pérez-Laines J; Molina-Berríos A; López-Muñoz R
Molecules; 2019 May; 24(10):. PubMed ID: 31109107
[TBL] [Abstract][Full Text] [Related]
2. Nitro aspirin (NCX4040) induces apoptosis in PC3 metastatic prostate cancer cells via hydrogen peroxide (H
Chinnapaka S; Zheng G; Chen A; Munirathinam G
Free Radic Biol Med; 2019 Nov; 143():494-509. PubMed ID: 31446057
[TBL] [Abstract][Full Text] [Related]
3. NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes.
Ricciotti E; Dovizio M; Di Francesco L; Anzellotti P; Salvatore T; Di Francesco A; Sciulli MG; Pistritto G; Monopoli A; Patrignani P
J Immunol; 2010 Feb; 184(4):2140-7. PubMed ID: 20065114
[TBL] [Abstract][Full Text] [Related]
4. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Drozdowicz D; Kwiecień S; Pajdo R; Ptak A; Pawlik M; Hahn E
Dig Liver Dis; 2000 Oct; 32(7):583-94. PubMed ID: 11142556
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway.
Song JM; Upadhyaya P; Kassie F
Carcinogenesis; 2018 Jul; 39(7):911-920. PubMed ID: 29982425
[TBL] [Abstract][Full Text] [Related]
6. Cox-2-selective inhibitors: the new super aspirins.
DeWitt DL
Mol Pharmacol; 1999 Apr; 55(4):625-31. PubMed ID: 10101019
[No Abstract] [Full Text] [Related]
7. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
8. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
[TBL] [Abstract][Full Text] [Related]
10. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of nitric oxide-aspirin hybrid drugs.
Turnbull CM; Rossi AG; Megson IL
Expert Opin Ther Targets; 2006 Dec; 10(6):911-22. PubMed ID: 17105376
[TBL] [Abstract][Full Text] [Related]
12. Dual COX-inhibitors: the answer is NO?
Fiorucci S; Antonelli E
Curr Top Med Chem; 2005; 5(5):487-92. PubMed ID: 15974943
[TBL] [Abstract][Full Text] [Related]
13. NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives.
Zacharowski P; Breese E; Wood E; Del Soldato P; Warner T; Mitchell J
Eur J Pharmacol; 2005 Jan; 508(1-3):7-13. PubMed ID: 15680249
[TBL] [Abstract][Full Text] [Related]
14. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of aspirin and NO-releasing aspirins on differentiation, maturation and function of human monocyte-derived dendritic cells in vitro.
Bufan B; Mojsilović S; Vucićević D; Vucević D; Vasilijić S; Balint B; Colić M
Int Immunopharmacol; 2009 Jul; 9(7-8):910-7. PubMed ID: 19341823
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.
Basudhar D; Cheng RC; Bharadwaj G; Ridnour LA; Wink DA; Miranda KM
Free Radic Biol Med; 2015 Jun; 83():101-14. PubMed ID: 25659932
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Cytotoxicity of NCX4040, the Non-Steroidal Anti-Inflammatory NO-Donor, in Human Ovarian Cancer Cells.
Sinha BK; Tokar EJ; Bortner CD
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955744
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs.
Hida T; Leyton J; Makheja AN; Ben-Av P; Hla T; Martinez A; Mulshine J; Malkani S; Chung P; Moody TW
Anticancer Res; 1998; 18(2A):775-82. PubMed ID: 9615719
[TBL] [Abstract][Full Text] [Related]
19. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Kodela R; Chattopadhyay M; Goswami S; Gan ZY; Rao PP; Nia KV; Velázquez-Martínez CA; Kashfi K
J Pharmacol Exp Ther; 2013 Apr; 345(1):85-94. PubMed ID: 23349335
[TBL] [Abstract][Full Text] [Related]
20. Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines.
Tesei A; Rosetti M; Ulivi P; Fabbri F; Medri L; Vannini I; Bolla M; Amadori D; Zoli W
J Transl Med; 2007 Oct; 5():52. PubMed ID: 17971198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
